Ациклостад

Quick links to important sections

Ациклостад

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ациклостад

Property Description
Active Ingredient Acyclovir (Aciclovir)
Pharmacological Class Antiviral
Dosage Forms Tablet, Cream/Ointment, Solution for Injection
General Purpose To inhibit the spread of specific viruses
Origin Synthetic (laboratory-created)

What is Ациклостад and What is its Purpose?

Ациклостад is a specific brand of medication whose active component is Acyclovir (Aciclovir), a substance recognized for its efficacy against certain viral pathogens. It is classified as a synthetic antiviral agent, meaning the core molecule was created in a laboratory.

The general purpose of this medicine is to help the body fight off specific viral infections by slowing down the virus’s ability to multiply. This focused action is fundamental to reducing the overall viral activity, which in turn helps to manage the outbreak and minimize its impact.

Acyclovir: The Composition and Forms of Acyclostad

The medicine is a single-ingredient product, containing only the active substance Acyclovir. Acyclostad is commonly supplied in various dosage forms, including tablets for internal (oral) use and creams for localized topical application on the skin.

How Ациклостад Differs from Antibiotics

Ациклостад belongs to the antiviral pharmacological class, making it fundamentally different from antibiotics, which fight bacteria. This distinction confirms that an antiviral is tailored to stop viruses, not bacteria. Understanding this specific focus ensures the medicine is used for its intended purpose against viral threats.

Regulatory References

  1. MedlinePlus - Acyclovir

What side effects are possible with Ациклостад?

Possible side effects and safety information

The safety profile of Acyclovir, the active substance in Ациклостад, is officially documented by government regulatory agencies (e.g., FDA and EMA) using a frequency-based classification system for adverse reactions.

Frequency-Classified Adverse Reactions

The majority of side effects are classified as Common (may affect up to 1 in 10 people) and typically involve the nervous or gastrointestinal systems. These frequently documented reactions include headache, dizziness, nausea, vomiting, and diarrhea.

Less frequent effects are categorized as Uncommon (skin reactions, accelerated hair loss) or Rare (severe allergic reactions like anaphylaxis or angioedema, and reversible increases in liver or kidney function indicators).

System-Organ Class and Serious Reactions

Adverse events are formally grouped into System-Organ Classes, with key areas being Gastrointestinal Disorders, Nervous System Disorders, Skin and Subcutaneous Tissue Disorders, and Renal and Urinary Disorders.

Serious adverse reactions are documented, although they are generally Very Rare. These include Acute Renal Failure and severe, though typically reversible, neurological effects such as confusion, hallucinations, and convulsions. The rare and severe condition Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome (TTP/HUS) has been reported in immunocompromised patients.

Population-Specific Safety Considerations

Official labels contain specific safety notes for certain patient groups. Because the medicine is cleared by the kidneys, older adults and individuals with pre-existing renal impairment may have increased systemic exposure and are at a higher risk of developing neurological side effects, requiring particular regulatory attention. The risk of renal issues is also documented when the medicine is co-administered with potentially nephrotoxic agents.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Acyclovir (Ациклостад) overdose is defined by the risk of systemic accumulation, which primarily affects the central nervous system (CNS) and the renal system. The information below details the documented manifestations and officially required emergency actions.


Documented Manifestations and Severe Outcomes

Overdose presentations documented in official sources include specific signs of CNS toxicity such as agitation, confusion, lethargy, somnolence, decreased consciousness, and seizures.

The most serious outcome is acute renal failure, which can result from the precipitation of Acyclovir crystals in the kidney tubules. In severe cases of systemic overdose, coma and death have been documented. This risk is officially noted to be higher in older adults and patients with pre-existing renal impairment or dehydration.


Actions Required by Regulatory Authorities

In the event of a suspected overdose, regulatory guidance requires the patient or caregiver to seek immediate medical attention and call the Poison Control Helpline.

Urgent medical assistance must be contacted immediately if the affected individual displays severe symptoms such as collapse, a seizure, trouble breathing, or an inability to be awakened.

No specific antidote is known for Acyclovir overdose. Management involves symptomatic and supportive treatment, including ensuring adequate hydration to help minimize renal injury. Hemodialysis is officially listed as a procedure that aids in removing the drug from the body.

Therapeutic Uses of Ациклостад

What Ациклостад Treats: Main Uses and Benefits

Ациклостад (Acyclovir) is relevant for easing certain symptoms associated with specific viral infections. This medication is commonly used to address conditions involving certain distressing symptoms of the herpes family of viruses.

Relief for Acute and Recurrent Herpes Outbreaks

The key indications include acute and recurrent episodes of Herpes Simplex Virus (HSV), such as cold sores and genital herpes, and infections caused by the Varicella-Zoster Virus (VZV), namely Shingles (Herpes Zoster) and Chickenpox (Varicella). It is applied across therapeutic domains where additional symptomatic support is needed. The benefit is commonly associated with periods of acute discomfort, when the medicine helps address symptom clusters that may become intense or disruptive, such as the localized pain, burning, and tingling sensations. The medication generally supports patients through difficult episodes by easing distress and contributing to improved comfort.

Supportive Management in Clinical Scenarios

The medication is relevant in conditions characterized by periods of heightened symptoms, including the need for supportive management against recurrence in immunocompromised patients. It is used in areas where short-term symptom management is appropriate and may assist in reducing the likelihood of symptomatic recurrences. This application generally helps maintain a sense of stability and supports patients during episodes of heightened discomfort.

Quick Fact: Relief for Acute Discomfort The medication is relevant in clinical settings that involve acute or unstable symptom patterns, including the management of symptoms related to the localized pain and blistering of Shingles.

Regulatory References

  1. NIH MedlinePlus Drug Information on Acyclovir

Eligibility and Restrictions for Use

Official Eligibility Rules for Ациклостад (Acyclovir)

Regulatory authorities define strict population eligibility for Acyclostad, focusing exclusively on who is officially allowed to use the medicine and who is prohibited.


Populations Prohibited (Contraindicated)

Category Regulatory Status
Hypersensitivity Strictly prohibited for patients with a known hypersensitivity to aciclovir, valaciclovir, or any excipient in the specific formulation.
Hereditary Metabolic Conditions Contraindicated for specific oral formulations containing excipients like lactose if the patient has rare hereditary problems such as galactose intolerance.

Conditional and Restricted Use

Eligibility is limited for populations where the body's ability to clear the medicine is reduced:

  • Renal Impairment: Patients with reduced kidney function, including elderly patients, require mandatory dose reduction due to the drug's primary elimination pathway.
  • Pregnancy and Lactation: Use during pregnancy is permitted only after a formal assessment concludes the potential benefit outweighs the possible risk. Caution is advised during breastfeeding as aciclovir is detected in breast milk.
  • Age Groups: The topical cream is generally restricted to adolescents and adults (12 years and older). For oral use, children 2 years and older are typically approved for specific indications, but infants require specific medical determination.

These constraints define the official eligibility framework, ensuring the medicine is used only by regulated populations.

What should I know about interactions with other medicines?

Official Interaction Profile for Ациклостад (Acyclovir)

This section summarizes officially documented interactions based on authoritative government regulatory sources.

Interaction Type Interacting Medicines/Classes Documented Effect
Exposure Modification Probenecid, Cimetidine Both reduce Acyclovir renal clearance by competing for tubular secretion, increasing Acyclovir plasma exposure (AUC).
Mycophenolate Mofetil Co-administration increases plasma exposure of both Acyclovir and the inactive metabolite of Mycophenolate Mofetil.
Theophylline Acyclovir may increase the serum levels of Theophylline.
Additive Toxicity Other Nephrotoxic Drugs Concomitant use increases the risk of renal impairment due to additive effects.
Pharmacodynamic Zidovudine Fatigue has been officially associated with the combined use of these two antiviral agents.

The most significant interactions are pharmacokinetic, driven by the competition for the renal tubular secretion pathway, which can formally elevate Acyclovir levels in the bloodstream. This increase in exposure carries a specific caution for elderly patients and individuals with impaired renal function. No interactions with food are known to affect Acyclovir absorption, and mandatory dose separation times for interactions are not required in the regulatory labeling. The profile formally identifies specific substances that either alter drug exposure or pose an additive toxicity risk.

Mechanism of Action

Selective Activation and DNA Synthesis Blockade

The unique mechanism of Acyclovir begins with its selective activation by the Viral Thymidine Kinase (vTK) enzyme, which is produced primarily by the replicating virus inside infected cells. This critical initial step transforms the inert drug (a prodrug) into an active molecule, primarily directing the drug's action to cells where the virus is actively present. This enzymatic dependency defines the drug's selective activation, meaning conversion is minimal or absent in non-infected host cells.

Once fully activated, the drug molecule acts as a DNA chain terminator. It competes with the natural building blocks and is incorporated into the growing Viral DNA strand by the Viral DNA Polymerase. Since the incorporated drug lacks the necessary chemical structure for further growth, it prevents the continuance of the viral DNA chain, resulting in an irreversible termination of synthesis. This core mechanism prevents the virus from successfully producing new genetic material, a necessary step for replication. The physiological result is a molecular constraint on viral propagation, limiting the virus's dissemination to neighboring host cells.

Dosage and Administration Information

How to Use Ациклостад

This section outlines the general principles of administering Acyclostad (Acyclovir), focusing on standard usage patterns and administration conditions.


Administration Guidelines

Category Usage Instruction
Route of Administration The medicine is delivered via Oral (tablet, suspension), Intravenous (IV) Infusion, Topical (cream), and Ophthalmic routes.
Standard Dosing Oral adult doses typically range from 200 mg to 800 mg per administration. IV doses are weight-based (e.g., 5 mg/kg to 10 mg/kg).
Dosing Frequency Use is classified as high-frequency (e.g., five times daily for acute treatment) or low-frequency (e.g., two to four times daily for maintenance/suppressive therapy).

Procedural and Population-Specific Rules

Contextual Intake and Preparation:

Oral forms may be taken with or without food; standard practice involves consumption with a full glass of water to aid in systemic hydration and kidney function. Intravenous solution requires dilution and must be administered as a slow infusion over a period of at least one hour; rapid injection is strictly prohibited.

Dose Adjustment Protocols:

The dosage is reduced for patients with renal impairment (kidney function compromise), with calculations based on creatinine clearance. For older adults, a dose reduction may be necessary due to age-related decline in renal function. Pediatric doses are determined based on the child's body weight or surface area.

Missed Dose Guidance:

If a scheduled oral dose is missed, it should be taken when remembered, unless it is nearly time for the next dose, in which case the missed dose is skipped (the subsequent dose is not doubled). The treatment course typically lasts 5 to 10 days for acute episodes but may continue for months in suppressive therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Compound Z in Osteoarthritis (OA)

Research has examined the potential effects of Compound Z on joint mobility and pain in patients with Osteoarthritis (OA).

  • Pain and Mobility: Studies evaluated whether Compound Z had an impact on patient-reported pain scores and objective measures of joint function.
  • Time-to-Action: One study evaluated the effects of Z on OA symptoms and observed a time-to-onset of action. This research explored how quickly changes in pain perception were noted following initiation of the treatment protocol.
  • Mechanism of Action: Studies propose that Z may influence inflammatory pathways. Research is ongoing to evaluate its potential impact on cartilage degradation.

Combination Therapy: Z and Compound Y

A line of research investigated the effects of combining Compound Z with Compound Y.

  • Comparative RCT: The combination of Z with Compound Y was compared to Z alone in a 12-week RCT, and differences in outcome X were noted.
  • Treatment Profile: This combined approach was the subject of research to explore its profile as a treatment option. Researchers focused on whether the combination demonstrated a different safety and tolerability profile compared to the single agents.

Safety and Patient Considerations

Adverse events reported in clinical trials were generally consistent with those observed in comparable treatments. Information regarding the suitability of Z for any patient is assessed by a healthcare professional.

  • Organ Function: Clinical trials included regular monitoring of kidney function.
  • Specific Patient Groups: Studies examining the use of Z in patients with pre-existing liver disease remain limited.

Summary of Research

Overall, Z has been the subject of research across several joint pain indications to investigate its properties. The body of evidence reports the findings of clinical evaluations.

Key Studies & References

  1. Integrated neurobehavioral and organ-specific safety profiling of baicalin: acute/subacute toxicity studies (Supporting information on organ function monitoring/safety profile structure)

Frequently Asked Questions (FAQ)

Common questions about Ациклостад (FAQ)

Q: Is Ациклостад the same drug as Zovirax?

Ациклостад contains the active ingredient Acyclovir. Official regulatory documents indicate that Zovirax is a brand name product that also contains Acyclovir. Therefore, the core medicine ingredient is the same.


Q: What types of viruses is Ациклостад typically used against?

Regulatory sources state that this medicine is intended for use against infections caused by specific pathogens. Official information indicates the medicine is used against viruses such as Herpes Simplex Virus (HSV) and Varicella-Zoster Virus (VZV).


Q: Is it generally acceptable to use Ациклостад while pregnant?

Regulatory documents state that use during pregnancy is officially permitted only if the potential benefit is determined to outweigh any potential risk to the fetus. Regulatory documents outline that this assessment is to be made by a healthcare provider.


Q: Does the package insert for Ациклостад mention use during breastfeeding?

Official information notes that the active substance, aciclovir, has been detected in breast milk. Caution is generally advised regarding administration to a nursing mother.


Q: Why do official documents mention keeping the affected area clean when using the cream?

Official patient instructions for the topical cream advise patients to wash their hands before application and to ensure the face and/or lips are clean and dry. This guidance is intended to promote proper application and hygiene.


Q: What are the general population limitations mentioned in official drug information for Ациклостад?

Population limitations are officially documented, primarily for patients with a known hypersensitivity to the drug, reduced kidney function (including older adults), and children under certain ages for specific formulations. A healthcare provider uses this information to determine eligibility.


Q: Can I stop using Ациклостад as soon as my symptoms improve?

Regulatory documents outline that the duration of use is typically for a set number of days for acute episodes, and the medicine is generally intended to be used for the full prescribed course.


Q: Is it important to keep well-hydrated while taking Ациклостад?

Official guidance suggests drinking plenty of water, as maintaining hydration is linked to supporting proper kidney function during treatment.


Q: How quickly does Ациклостад usually start to work?

Regulatory summaries indicate that for recurrent infections, therapy should be initiated as early as possible after the first signs of an infection appear. This early initiation is referenced in regulatory information as a factor in managing recurrent outbreaks.


Q: Is long-term use of Ациклостад generally examined in research?

Regulatory documents acknowledge that oral use may continue for periods up to 12 months for the prevention of recurrent outbreaks of genital herpes. This practice is part of the established therapeutic use of the drug.


Q: Is Ациклостад a prescription-only medicine in most countries?

The oral and intravenous forms of the medicine are generally available only with a healthcare provider's prescription. The topical cream, which is often used for cold sores, may be available without a prescription in some locations.


Q: What is the difference between Acyclovir and Ациклостад?

Acyclovir is the active drug ingredient. Ациклостад is the specific brand name under which the drug is marketed.


Q: What is the role of Ациклостад in managing recurring outbreaks?

The medicine is officially indicated for the suppression, which means the prevention of recurrences, of herpes simplex infections. The management of recurring outbreaks using this medicine is often described as prophylactic or suppressive use.


Q: Does the cream formulation of Ациклостад work differently than the tablets?

The core antiviral mechanism, which is blocking viral DNA, is the same for the active substance in all forms. The cream formulation is restricted to cutaneous use (on the skin) and not mucous membranes.


Q: Is Ациклостад known to cause drowsiness or affect driving?

Regulatory information documents that the drug can cause central nervous system side effects such as dizziness, confusion, and sleepiness (somnolence), particularly in patients with kidney impairment. These central nervous system effects are documented in official information, and individuals should be mindful of how they respond to the medicine.


Q: How is Ациклостад different from antiviral medicines used for the flu?

The medicine’s classification and specific target mechanism define its use against herpes viruses, distinguishing it from antiviral medicines that target influenza viral pathways.


Q: Are there any known severe or serious side effects associated with Ациклостад?

Official regulatory documents do describe the occurrence of serious, though generally rare, adverse reactions. These have included acute renal failure, severe neurological effects such as confusion and convulsions, and a rare condition known as TTP/HUS in immunocompromised patients.


Q: What are the most common reasons why a doctor might prescribe Ациклостад?

Official documents indicate the medicine is used for treating specific infections. These common indications include those caused by herpes simplex virus (HSV), herpes zoster (shingles), and varicella zoster (chickenpox).


Q: Can Ациклостад be used by people who are immunocompromised?

Regulatory documents indicate the medicine is officially used for the prophylaxis (prevention) and treatment of herpes simplex infections in immunocompromised patients. Official documentation indicates that specific dosing regimens are described for use in this patient population.


Q: What has clinical research indicated about the general tolerability of Ациклостад?

Clinical trial data summarized in regulatory documents reports that adverse events were generally consistent with those observed in comparable treatments. The majority of side effects are classified as Common, such as headache and nausea.


Q: What are the general guidelines for children's use of Ациклостад?

Official guidelines indicate that children two years and older are typically given adult dosages for some indications. For infants and children below two years, specific, weight-based dosages are described in the regulatory literature.


Q: Can Ациклостад be used on broken skin or inside the mouth?

Regulatory documentation states the topical cream is intended for external use on the lips and face. Regulatory documents advise against application to human mucous membranes, which includes the inside of the mouth or nose.


Q: Does regulatory information note any effects of Ациклостад on mental clarity or mood?

Regulatory information documents that very rare adverse effects on the nervous system can occur. These have included confusion, hallucinations, agitation, and psychotic symptoms.


Q: What is the shelf life or general stability of Ациклостад tablets?

Official storage instructions require the tablets to be stored at room temperature, typically between 20 C and 25 C. The medicine must also be protected from light, moisture, and freezing to maintain its stability.


Q: Is there research evidence supporting the use of Ациклостад to prevent outbreaks?

Yes, official documents confirm that the medicine is indicated and researched for prophylaxis, which is the prevention of recurrences of herpes simplex infections in specific patient groups.


Q: Is it commonly misunderstood that Ациклостад cures the infection completely?

Official labeling documents that the medicine is not a cure for herpes infections. It is noted that the virus may still remain in the body, and symptoms may occur again later.


Q: Does the drug's classification imply its use only for specific types of viral infections?

Yes, the medicine's classification as an antiviral agent is linked to a specific mechanism of action that selectively targets enzymes produced by herpes viruses. This defines its therapeutic scope to those specific viral infections.


Q: Can I use Ациклостад if I am allergic to other antiviral medications?

The medicine is strictly contraindicated for patients with a known hypersensitivity or severe allergic reaction to aciclovir or valaciclovir. General allergy to other antiviral medicines is not a formal contraindication but is information a healthcare provider should assess.


Q: Can Ациклостад cause sensitivity to sunlight?

Official patient information notes that the medicine can make the skin more sensitive to the sun. This effect is known as photosensitivity and may increase the risk of sunburn.


Q: What does the research say about the use of Ациклостад for Chickenpox?

Official documents indicate that the medicine is used for the treatment of varicella zoster, which is the virus that causes chickenpox infections. Specific use conditions and dosing regimens for this indication are described in regulatory documents for both children and adults.


Q: Are there different strengths or dosages of Ациклостад tablets?

Official documents detail adult oral doses ranging from 200 , mg to 800 , mg per administration, with the specific dose determined by the indication. These different doses reflect the varied treatment needs outlined in regulatory documents.

How should Ациклостад be stored and disposed of?

How to Store and Dispose of Acyclostad

The official storage and disposal guidelines for Acyclostad (Aciclovir) are defined by regulatory authorities to maintain product integrity and ensure safety.

Storage Requirement Official Guideline
Temperature Store at a temperature not exceeding 25 C or 30 C (varies by formulation); some products require no special conditions.
Protection Must be protected from moisture and must not be frozen.
Container Keep the product in its original container and ensure the container is tightly closed.

Handling and Disposal

The medicine must be kept out of the sight and reach of children at all times. Disposal of any unused or expired Acyclostad must be done in accordance with local requirements for pharmaceutical waste. The product should generally not be disposed of via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ациклостад found in:

A-Z Index: